Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

GlaxoSmithKline: European Commission Authorizes Nimenix

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 02:24pm CEST

GlaxoSmithKline PLC (>> GlaxoSmithKline plc), the drug company, said Friday that the European Commission has granted marketing authorization for Nimenrix, Meningococcal group A, C, W-135 and Y conjugate vaccine, for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.

-Shares at 1207 GMT, up a penny, or 0.04%, at 1,420.5 pence valuing the company at GBP71.61 billion.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; [email protected]

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 GLAXOSMITHKLINE : Hikma sales blow
05/22 WILSON THERAPEUTICS : Strengthens its Board of Directors by the Appointments of ..
05/20 GLAXOSMITHKLINE : joins NMSI College Readiness Program effort
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
05/18 GLAXOSMITHKLINE : GSK announces NEJM publication of positive phase III study inv..
05/18 GLAXOSMITHKLINE : Data on Vaccines Detailed by Researchers at GlaxoSmithKline pl..
05/12 GLAXOSMITHKLINE : Top-10 Glaxo investor Woodford sells out, criticises board
05/12 GLAXOSMITHKLINE : GSK announces headline phase III results of mepolizumab in pat..
05/11 GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Report Details of New Stu..
More news
Sector news : Pharmaceuticals - NEC
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/22 'Safer' Dividend Healthcare Dog's 55% Top Gain Equals Sum Of Four Tailing It ..
05/22 Healthcare Dogs See Psychemedics Tops By Gains In May
05/22 Tracking Tweedy Browne Portfolio - Q1 2017 Update
05/19 I'm Surprised That They're Surprised
05/18 Glaxo's successful late-stage study of mepolizumab in rare inflammatory disor..
Advertisement
Financials ( GBP)
Sales 2017 30 004 M
EBIT 2017 8 327 M
Net income 2017 4 252 M
Debt 2017 13 983 M
Yield 2017 4,90%
P/E ratio 2017 19,10
P/E ratio 2018 16,57
EV / Sales 2017 3,14x
EV / Sales 2018 3,01x
Capitalization 80 326 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 17,7  GBP
Spread / Average Target 8,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Roy Malcolm Anderson Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC4.58%104 904
JOHNSON & JOHNSON10.68%342 817
ROCHE HOLDING LTD.15.18%237 610
NOVARTIS AG6.68%213 719
PFIZER INC.-1.32%191 279
MERCK & CO., INC.10.29%175 160
More Results